Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocular Therapeut (NQ: OCUL )

3.190 +0.010 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ocular Therapeut

< Previous 1 2 Next >
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
From Ocular Therapeutix, Inc.
Via Business Wire
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
From Ocular Therapeutix
Via Business Wire
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
From Ocular Therapeutix, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.